pharmaphorum

JUNE 8, 2022

Roche has secured its first regulatory approval for mosunetuzumab, a first-in-class CD20xCD3 bispecific antibody, as a treatment for patients with follicular lymphoma (FL) in the EU. Patients also have to undergo lymphodepleting chemotherapy to help prepare the body for the CAR-T cells.

Sales 105

Sales Antibody Licensing Licensing 105

pharmaphorum

AUGUST 16, 2020

ChAdOx1 – which is in large-scale phase 2/3 trials – was licensed by AZ in April and renamed AZD1222, and should be ready for first deliveries before the end of the year. It will be provided on a no-profit basis while the pandemic is ongoing.

Vaccination 111

Vaccination Vaccine Immune Response Trials 111

pharmaphorum

JUNE 16, 2022

It also probably marks the end of the road for crenezumab, which Roche’s Genentech subsidiary licensed from AC Immune in 2006 in a deal initially valued at $300 million. Before the end of the year, Roche should report results from two phase 3 studies in early-stage patients.

Trials 111

Trials Clinical Trials Clinical Trials Licensing 111

The Pharma Data

APRIL 12, 2023

Program uses Denali’s Antibody Transport Vehicle (ATV) technology to cross the blood-brain barrier (BBB) and aims to increase target engagement Biogen Inc. Nasdaq: DNLI) today announced that Biogen has exercised the option to license Denali’s Antibody Transport Vehicle (ATV): Amyloid beta program (ATV:Aβ).

Antibody 40

Antibody Development Engineer Licensing 40

pharmaphorum

DECEMBER 22, 2020

Since then Barron has been busy signing deals for therapies that are validated genetically, hoping that this will make them more likely to succeed in the clinic. The latest deals include a license agreement with San Diego-based Ligand Therapeutics , which has a subsidiary producing technology for neurological disorders.

Licensing 52

Licensing Licensing Genetics Sales 52

The Pharma Data

DECEMBER 17, 2020

NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. TARRYTOWN, N.Y. , 17, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc.

Antibody 52

Antibody Medicine Production Trials 52

pharmaphorum

JUNE 7, 2022

million licensing agreement with Alectos Therapeutic, as it continues to rebuild a pipeline behind its side-lined Alzheimer’s therapy Aduhelm. It’s not the first time that Biogen has licensed rights to a drug targeting lysosomal function in Parkinson’s disease.

Licensing 80

Licensing Licensing Gene Therapy Genetics 80

pharmaphorum

NOVEMBER 30, 2020

The drug is an antibody-drug conjugate where a monoclonal antibody is linked to monomethyl auristatin, a cancer-killing “payload” It is targeted against AXL, a signalling molecule that is overexpressed in several haematologic and solid malignancies.

Development 52

Development Drugs Antibody Immune Response 52

Velocity Clinical Research

AUGUST 8, 2024

It’s been just over a year since the monoclonal antibody Lecanemab received traditional approval from the FDA as a treatment for Alzheimer’s disease. We understand the tau protein, that some people have inflammation in the brain or a genetic predisposition. And the more we learn, the more possibilities that creates for treatment.”

Clinical Trials 105

Clinical Trials Clinical Trials Genetics Clinical Research 105

pharmaphorum

JUNE 16, 2021

California biotech Ambrx Biopharma is hoping to raise $126 million from a listing on the New York Stock Exchange (NYSE) that will be used in part to fund clinical development of ARX-788, its HER2-targeting antibody drug conjugate (ADC). billion upfront, when it licensed the ADC from Daiichi Sankyo in 2019.

Antibody 59

Antibody Sales Drugs Trials 59

Pharmaceutical Technology

MARCH 2, 2023

ImmunoGen has announced an agreement granting rights to Vertex Pharmaceuticals to carry out research using antibody-drug conjugate (ADC) technology for the discovery of new targeted conditioning agents. The research using ImmunoGen’s technology will enable the discovery of the agents for use with gene editing.

Gene Editing 130

Gene Editing Gene Development Research 130

pharmaphorum

NOVEMBER 19, 2021

Gilead Sciences has forged closer ties to its cancer drug partner Arcus Biosciences , although a licensing deal doesn’t go as far as the takeover that some market commentators have been predicting. Antibodies consists of two components – called Fab and Fc – with Fab handling targeting of the molecule and Fc responsible for function.

Drugs 52

Drugs Antibody Development Engineer 52

Delveinsight

DECEMBER 1, 2020

BASE10 Collaborates with DNA Link for COVID-19 Antibody Test Research. US-based BASE10 Genetics and Korean firm DNA Link announced a collaboration on a research project to appraise the usability of the DNA Link’s antibody test, AccuFind COVID-19 IgG, in a healthcare setting. CABOMETYX is already approved in the U.S.

Antibody 52

Antibody DNA Clinical Trials Clinical Trials 52

pharmaphorum

SEPTEMBER 17, 2020

There are two antibodies already on the market that target PCSK9 – Amgen’s Repatha (evolocumab) and Sanofi/Regeneron’s Repatha (alirocumab) – but these require subcutaneous injection every two to four weeks.

Drugs 66

Drugs Antibody Sales Branding 66

pharmaphorum

AUGUST 7, 2020

Inhibition of LRRK2 activity may slow the progression of Parkinson’s disease in patients with and without known genetic risks based on restoration of lysosomal function.

Bacteria 69

Bacteria Marketing Licensing Licensing 69

The Pharma Data

OCTOBER 28, 2020

NASDAQ: REGN) today announced positive, prospective results from an ongoing Phase 2/3 seamless trial in the COVID-19 outpatient setting showing its investigational antibody cocktail, REGN-COV2, met the primary and key secondary endpoints. Regeneron Pharmaceuticals, Inc. Yancopoulos , M.D., President and Chief Scientific Officer of Regeneron.

Antibody 40

Antibody Trials Production Clinical Trials 40

The Pharma Data

DECEMBER 5, 2020

NASDAQ: REGN) today announced updated data for REGN5458, a BCMAxCD3 bispecific antibody, from the Phase 1 portion of a Phase 1/2 trial in patients with relapsed or refractory (R/R) multiple myeloma. These allow for the creation of bispecific antibodies that closely resemble natural human antibodies with no linkers or artificial sequences.

Antibody 40

Antibody Production Trials Medicine 40

pharmaphorum

FEBRUARY 5, 2021

23andMe is best known for its saliva-based health and ancestry DNA testing targeted at consumers, but the company also uses its genetic database to look for new targets for drug development. That’s been achieved thanks to a group of 10 million people worldwide who have agreed to allow their genetic data to be used for research.

Genetics 52

Genetics DNA Life Science Clinical Trials 52

pharmaphorum

JUNE 2, 2021

The deal gives Amgen rights to the KHK4083 antibody in all countries except Kyowa’s home market of Japan, and is back-loaded with potential milestone payments worth another $850 million plus royalties on sales. Kyowa will co-promote the drug in the US if approved, with opt-in rights in some other countries as well.

Drugs 52

Drugs Licensing Licensing Sales 52

FDA Law Blog

DECEMBER 7, 2022

This product was developed by uniQure prior to being licensed to CSL Behring. We know, for example, the use of viral vectors results in antibody production that could inhibit future administration of gene therapies using the same or similar viruses, which will inform treatment decisions by patients with their doctors.

Gene Therapy 119

Gene Therapy Gene FDA Approval Production 119

pharmaphorum

APRIL 12, 2021

Sanofi has licensed a potential inflammatory diseases drug from Manchester University spin-off C4X Discovery Holdings in a deal worth up to €414 million ($492 million). This follows a tie-up between C4XD, Sano Genetics and BenevolentAI to accelerate research into inflammatory bowel disease, which was signed in February.

Drugs 52

Drugs In-Vivo Licensing Licensing 52

The Pharma Data

NOVEMBER 29, 2020

Y-mAbs Therapeutics has a target action date of November 30 for its Biologics License Application (BLA) for Danyelza (naxitamab) for patients with relapsed/refractory high-risk neuroblastoma. The drug was developed by researchers at Memorial Sloan Kettering Cancer Center and exclusively licensed to Y-mAbs.

Genetic Disease 52

Genetic Disease Antibody Licensing Licensing 52

pharmaphorum

DECEMBER 21, 2020

billion acquisition of VelosBio and its anti-ROR1 antibody-drug conjugate (ADC) VLS-101, as well as a partnership with Dragonfly Therapeutics for a cancer programme based on the biotech’s TriNKET natural killer (NK) cell engager platform. billion alliance with Taiho and Astex for cancer antibodies, including a KRAS drug, and a $4.2

Immune Response 59

Immune Response Sales Antibody Drugs 59

pharmaphorum

JUNE 7, 2021

The Scottish agency has allowed restricted use of the drug by NHS Scotland, limiting it to patients who are clinically ineligible for or refractory to treatment with Takeda’s Adcetris (brentuximab vedotin), an antibody-drug conjugate (ADC) also used for relapsed CTCL. Other decisions.

Drugs 52

Drugs Licensing Licensing Antibody 52

The Pharma Data

MARCH 4, 2021

Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for Dupixent ® (dupilumab) as an add-on treatment for children aged 6 to 11 years with uncontrolled moderate-to-severe asthma. Detailed results from this Phase 3 trial will be published later this year. Source link:[link].

Genetics 52

Genetics Medicine Antibody Trials 52

The Pharma Data

OCTOBER 30, 2020

NASDAQ: REGN) received today a recommendation from the independent data monitoring committee (IDMC) for the REGN-COV2 antibody cocktail treatment trials for COVID-19 that the current hospitalized patient trial be modified. TARRYTOWN, N.Y. , Regeneron Pharmaceuticals, Inc.

Production 52

Production Antibody Manufacturing Trials 52

The Pharma Data

JANUARY 17, 2021

These models are engrafted with mouse tumors derived from the same strain background; this genetic similarity between tumor and host prevents the host from rejecting the tumor. Standard mice may develop anti-drug antibodies (ADA), which can neutralize the therapeutic or even trigger anaphylaxis.

Genetic Engineering 40

Genetic Engineering Genetics Engineer Immune Response 40

The Pharma Data

JULY 27, 2021

Acquisition Complements Amgen’s Antibody Research Capabilities Across Therapeutic Areas Acquisition Includes a Portfolio of Early-Stage Oncology Assets, Including a Phase 1 Bispecific Antibody for Patients With Advanced Prostate Cancer. billion in cash. Reese, M.D., executive vice president of Research and Development at Amgen.

Production 52

Production Antibody Sales Development 52

The Pharma Data

OCTOBER 26, 2020

AR-711 is a fully human immunoglobulin 1, or IgG1, monoclonal antibody discovered from screening the antibody secreting B-cells of convalescent COVID-19 patients. AR-711 is an in-licensed mAb that is directed against the receptor binding domain of the SARS-Cov 2 virus. About AR-711. The Company is utilizing its proprietary ?PEX

Antibody 52

Antibody Genetic Engineering Development Clinical Trials 52

The Pharma Data

DECEMBER 8, 2020

Since partnering with Eli Lilly to produce the first monoclonal antibody therapy approved for mild-to-moderate COVID-19 patients, antibody discovery company AbCellera is going big on the Nasdaq. The assumption is SciNeuro will start with Parkinson’s disease and pain in addition to rare genetic diseases, after scaling up staffing. .

RNA 52

RNA Antibody Life Science Protein 52

XTalks

SEPTEMBER 17, 2020

Symptoms and Etiology: Characterized by progressive muscle weakness and atrophy, Duchenne muscular dystrophy (DMD) is an X-linked genetic condition that primarily affects males. Symptoms and Etiology: Individuals with the rare genetic disorder congenital generalized lipodystrophy have nearly no body fat and are, instead, extremely muscular.

Trials 98

Trials Gene Hormones Clinical Trials 98

The Pharma Data

JUNE 7, 2022

1-2 Lebrikizumab is a novel, monoclonal antibody (mAb) that binds to the interleukin-13 (IL-13) protein with high affinity to specifically prevent the formation of IL-13R?1/IL-4R? With these data, Lilly plans to submit a Biologics License Application (BLA) to the U.S. Almirall S.A.’s ’s Chief Scientific Officer.

Trials 40

Trials Clinical Trials Clinical Trials Medicine 40

The Pharma Data

NOVEMBER 3, 2020

Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, announced today the U.S. It may also allow for priority or rolling review of a company’s Biologics License Application (BLA). LEXINGTON, Mass., About LogicBio Therapeutics.

Clinical Trials 40

Clinical Trials Clinical Trials Gene Editing Genome 40

The Pharma Data

OCTOBER 22, 2020

Monalizumab may re-establish a broad anti-tumor response mediated by NK and T cells, and may enhance the cytotoxic potential of other therapeutic antibodies (André et al, Cell 2018). About Cetuximab: Cetuximab is an anti-EGFR monoclonal antibody. overall response rate, a median time to progression of 2.3

Clinical Trials 40

Clinical Trials Clinical Trials Trials Antibody 40

The Pharma Data

DECEMBER 30, 2020

For MVR-T3011 intratumoural program, a landmark license program was achieved with Shanghai Pharma along with a validating strategic investment. ImmVira was founded on May 18, 2015 as a biotechnology company focused on genetically modified oncolytic viruses (“OV”) as potential cancer therapeutics.

Development 40

Development Trials Manufacturing Compliance 40

The Pharma Data

APRIL 27, 2023

It is also an off-the-shelf therapy, meaning that people do not have to wait for cell collection and genetic engineering before starting treatment, which could be particularly important for patients who are at a high-risk of their disease progressing. A final decision is expected from the European Commission (EC) in the near future.

Genetic Engineering 40

Genetic Engineering Clinical Development Antibody Medicine 40

The Pharma Data

SEPTEMBER 20, 2020

To learn more about Amgen ‘s innovative pipeline with diverse modalities and genetically validated targets, please visit AmgenOncology.com. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Cancer Genet. References.

Medicine 52

Medicine Production Sales Clinical Trials 52